Hims & Hers Health (NYSE:HIMS) Stock Price Down 2% After Insider Selling

Key Points

• Hims & Hers Health stock fell 2% after CFO Oluyemi Okupe sold over 11,000 shares, reducing his ownership by 9.02% and triggering concerns among investors.
• Analysts have lowered their target prices for Hims & Hers Health, with the average target now at $38.92 and several firms issuing "hold" or "sell" ratings.
• The company's recent earnings report showed a miss on EPS estimates and revenue slightly below expectations, raising questions about its financial performance moving forward.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) were down 2% on Friday after an insider sold shares in the company. The company traded as low as $42.89 and last traded at $43.25. Approximately 5,184,703 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 33,244,348 shares. The stock had previously closed at $44.12.

Specifically, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89. Following the completion of the sale, the chief financial officer directly owned 116,806 shares of the company's stock, valued at approximately $5,103,254.14. The trade was a 9.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,571 shares of Hims & Hers Health stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.53, for a total transaction of $114,486.63. Following the sale, the insider directly owned 150,450 shares of the company's stock, valued at $6,699,538.50. This represents a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HIMS shares. Truist Financial decreased their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday, August 18th. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research report on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Price Performance

The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company has a 50 day moving average price of $50.42 and a 200 day moving average price of $45.83. The firm has a market cap of $9.76 billion, a PE ratio of 53.96, a price-to-earnings-growth ratio of 2.97 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same period in the previous year, the company posted $0.06 EPS. Hims & Hers Health's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. Mariner LLC lifted its stake in Hims & Hers Health by 77.4% in the 4th quarter. Mariner LLC now owns 19,943 shares of the company's stock valued at $482,000 after buying an additional 8,699 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Hims & Hers Health by 71.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,002 shares of the company's stock worth $435,000 after purchasing an additional 7,476 shares during the period. Stifel Financial Corp purchased a new position in shares of Hims & Hers Health during the 4th quarter worth $257,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Hims & Hers Health by 291.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 420,348 shares of the company's stock worth $10,165,000 after purchasing an additional 312,908 shares during the period. Finally, Beacon Pointe Advisors LLC lifted its stake in shares of Hims & Hers Health by 71.2% during the 4th quarter. Beacon Pointe Advisors LLC now owns 52,172 shares of the company's stock worth $1,262,000 after purchasing an additional 21,690 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.